Sixfold Bioscience Ltd.
Research and experimental development on biotechnology · London
ActiveUnited KingdomIncorporated 2017Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 124 source facts · 20 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 124 source facts · 20 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 76
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2602_10687784_20251231
- Source archive
- Accounts_Monthly_Data-February2026.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-12-31
IXBRL · 128 source facts · 22 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 128 source facts · 22 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 80
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2503_10687784_20241231
- Source archive
- Accounts_Monthly_Data-March2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 123 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 123 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 76
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_1866_10687784_20231231
- Source archive
- Accounts_Monthly_Data-March2024.zip
Accounts to 2022-12-31
IXBRL · 118 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 118 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 74
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0003_10687784_20221231
- Source archive
- Accounts_Monthly_Data-February2023.zip
Accounts to 2021-12-31
IXBRL · 118 source facts · 22 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 118 source facts · 22 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 74
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0104_10687784_20211231
- Source archive
- Accounts_Monthly_Data-March2022.zip
Accounts to 2020-12-31
IXBRL · 117 source facts · 21 selected values
Not assessedlegacy record
Accounts to 2020-12-31
IXBRL · 117 source facts · 21 selected values
Not assessed
legacy record
- Reporting period
- 2020-01-01 to 2020-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 72
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0087_10687784_20201231
- Source archive
- Accounts_Monthly_Data-February2021.zip
Accounts to 2019-12-31
IXBRL · 101 source facts · 14 selected values
Not assessedlegacy record
Accounts to 2019-12-31
IXBRL · 101 source facts · 14 selected values
Not assessed
legacy record
- Reporting period
- 2019-01-01 to 2019-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 59
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0076_10687784_20191231
- Source archive
- Accounts_Monthly_Data-March2020.zip
Accounts to 2018-12-31
IXBRL · 88 source facts · 16 selected values
Not assessedlegacy record
Accounts to 2018-12-31
IXBRL · 88 source facts · 16 selected values
Not assessed
legacy record
- Reporting period
- 2018-01-01 to 2018-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 36
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0066_10687784_20181231
- Source archive
- Accounts_Monthly_Data-May2019.zip
Accounts to 2017-12-31
IXBRL · 22 source facts · 3 selected values
Not assessedlegacy record
Accounts to 2017-12-31
IXBRL · 22 source facts · 3 selected values
Not assessed
legacy record
- Reporting period
- 2017-03-23 to 2017-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 6
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- uk-gaap-full-2009-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0055_10687784_20171231
- Source archive
- Accounts_Monthly_Data-June2018.zip
Registered details
10687784- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2017-03-23
- Jurisdiction
- —
- Registered office
- THE IMPERIAL COLLEGE WHITE CITY INCUBATOR, TRANSLATION AND INNOVATION HUB, LONDON, GREATER LONDON, W12 0BZ, ENGLAND
Classification
1 SIC codes72110
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
22 matched grantsA Machine Learning-Driven Approach for Optimising RNA Therapeutic Delivery via Generative ModellingLeadLive
Innovate UK · Collaborative R&D · 2025-02-01 – 2029-01-31
£1,085,217
awarded
A Machine Learning-Driven Approach for Optimising RNA Therapeutic Delivery via Generative ModellingLeadActive
UKRI FLF · Fellowship · 2024-04-30 – 2028-04-29
£273,600
whole project
INDUCE: Development of siRNA-Mergo® therapeutics for lung indications.LeadInnovate UK · Collaborative R&D · 2023-11-01 – 2025-10-31 · with 1 other participant£256,727awarded
INDUCE: Development of siRNA-Mergo® therapeutics for lung indications.Lead
Innovate UK · Collaborative R&D · 2023-11-01 – 2025-10-31 · with 1 other participant
£256,727
awarded
Sixfold Bioscience Ltd.lead£256,727
Investigation of MergoⓇ mechanism of action by quantitative serum protein profiling.LeadInnovate UK · Collaborative R&D · 2023-08-01 – 2024-01-31 · with 1 other participant£8,995awarded
Investigation of MergoⓇ mechanism of action by quantitative serum protein profiling.Lead
Innovate UK · Collaborative R&D · 2023-08-01 – 2024-01-31 · with 1 other participant
£8,995
awarded
Sixfold Bioscience Ltd.lead£8,995
Medicines and Healthcare products Regulatory Agency£0
ENHANCE: Scaling up development of novel Mergo® formulations via optimised synthesis and high-throughput strategiesLeadInnovate UK · Collaborative R&D · 2023-07-01 – 2025-06-30 · with 1 other participant£293,231awarded
ENHANCE: Scaling up development of novel Mergo® formulations via optimised synthesis and high-throughput strategiesLead
Innovate UK · Collaborative R&D · 2023-07-01 – 2025-06-30 · with 1 other participant
£293,231
awarded
Sixfold Bioscience Ltd.lead£293,231
OligoY - a new class of oligonucleotide-based therapeutic meansLeadActive
UKRI FLF · Fellowship · 2022-06-05 – 2026-09-04
£859,711
whole project
SUMMIT: SiRNAs Utilising MergoⓇ delivery for post-Myocardial Infarction TreatmentLeadInnovate UK · Collaborative R&D · 2022-04-01 – 2024-03-31 · with 2 other participants£478,019awarded
SUMMIT: SiRNAs Utilising MergoⓇ delivery for post-Myocardial Infarction TreatmentLead
Innovate UK · Collaborative R&D · 2022-04-01 – 2024-03-31 · with 2 other participants
£478,019
awarded
Sixfold Bioscience Ltd.lead£478,019
Resilience-TARGET: RNA nanotechnology delivery platform for RNA therapiesLead
Innovate UK · Collaborative R&D · 2021-12-01 – 2022-01-31
£96,789
awarded
High-throughput approach for improving RNA nanoparticles as drug delivery agentsInnovate UK · Study · 2021-02-01 – 2023-01-31 · with 1 other participant£0awarded
High-throughput approach for improving RNA nanoparticles as drug delivery agents
Innovate UK · Study · 2021-02-01 – 2023-01-31 · with 1 other participant
£0
awarded
Sixfold Bioscience Ltd.£0
High-throughput approach for improving RNA nanoparticles as drug delivery agentsUKRI Inn.Scholar · Study · 2021-02-01 – 2023-01-31 · with 1 other participant£125,763whole project
High-throughput approach for improving RNA nanoparticles as drug delivery agents
UKRI Inn.Scholar · Study · 2021-02-01 – 2023-01-31 · with 1 other participant
£125,763
whole project
Imperial College LondonleadSixfold Bioscience Ltd.
Leveraging RNA nanotechnology for next-generation gene delivery systemsLeadUKRI FLF · Fellowship · 2021-02-01 – 2025-01-31 · with 3 other participants£852,747whole project
Leveraging RNA nanotechnology for next-generation gene delivery systemsLead
UKRI FLF · Fellowship · 2021-02-01 – 2025-01-31 · with 3 other participants
£852,747
whole project
Sixfold Bioscience LtdleadHenry Royce InstituteMedicines Discovery CatapultPharmidex
RAPOD: Rapid Assembly of Programmable Oligonucleotide Delivery systems for increased gene therapeutic loadLead
Innovate UK · Collaborative R&D · 2021-01-01 – 2021-03-31
£78,962
awarded
University of Newcastle Upon Tyne and Sixfold Bioscience LimitedInnovate UK · Knowledge Transfer Partnership · 2020-12-01 – 2022-11-30 · with 1 other participant
University of Newcastle Upon Tyne and Sixfold Bioscience Limited
Innovate UK · Knowledge Transfer Partnership · 2020-12-01 – 2022-11-30 · with 1 other participant
University of Newcastle upon Tynelead£126,331
Sixfold Bioscience Limited—
TARGET: RNA nanotechnology delivery platform for gene therapies, towards commercialization in cancerLeadInnovate UK · Study · 2020-11-01 – 2022-04-30 · with 1 other participant£239,855awarded
TARGET: RNA nanotechnology delivery platform for gene therapies, towards commercialization in cancerLead
Innovate UK · Study · 2020-11-01 – 2022-04-30 · with 1 other participant
£239,855
awarded
Sixfold Bioscience Ltd.lead£239,855
PropelLead
Innovate UK · EU-Funded · 2020-10-01 – 2022-12-31
£152,129
awarded
RNA nanotechnology for rapid and sustainable preclinical iteration of gene therapeuticsLeadInnovate UK · Collaborative R&D · 2020-10-01 – 2021-09-30 · with 1 other participant£139,021awarded
RNA nanotechnology for rapid and sustainable preclinical iteration of gene therapeuticsLead
Innovate UK · Collaborative R&D · 2020-10-01 – 2021-09-30 · with 1 other participant
£139,021
awarded
Sixfold Bioscience Ltd.lead£139,021
PropelLead
EU · EU-Funded · 2020-09-30 – 2022-12-31
£152,129
whole project
Propel
EU · EU-Funded · 2020-09-30 – 2022-12-31
£152,129
whole project
Covid-19 continuity: Effective measurement and analysis for optimisation of Sixfold’s functionally enhanced Programmable Oligonucleotide Delivery System (PODS) for delivery of Cell and Gene therapeuticsLead
Innovate UK · Feasibility Studies · 2020-06-01 – 2020-11-30
£57,607
awarded
Effective analysis and manipulation of the protein corona - increasing the efficacy of Sixfold’s delivery system for Cell and Gene therapeuticsLeadInnovate UK · Collaborative R&D · 2020-03-01 – 2021-02-28 · with 2 other participants£36,890awarded
Effective analysis and manipulation of the protein corona - increasing the efficacy of Sixfold’s delivery system for Cell and Gene therapeuticsLead
Innovate UK · Collaborative R&D · 2020-03-01 – 2021-02-28 · with 2 other participants
£36,890
awarded
Developing a method for in vivo quantification and analysis of Sixfold’s Programmable Oligonucleotide Delivery System (PODS) for siRNA cancer therapyLeadInnovate UK · Collaborative R&D · 2019-10-01 – 2021-03-31 · with 2 other participants£23,133awarded
Developing a method for in vivo quantification and analysis of Sixfold’s Programmable Oligonucleotide Delivery System (PODS) for siRNA cancer therapyLead
Innovate UK · Collaborative R&D · 2019-10-01 – 2021-03-31 · with 2 other participants
£23,133
awarded
Effective measurement and analysis for optimisation of Sixfold’s functionally enhanced Programmable Oligonucleotide Delivery System (PODS) for delivery of Cell and Gene therapeuticsLeadInnovate UK · Collaborative R&D · 2019-10-01 – 2020-12-31 · with 1 other participant£22,402awarded
Effective measurement and analysis for optimisation of Sixfold’s functionally enhanced Programmable Oligonucleotide Delivery System (PODS) for delivery of Cell and Gene therapeuticsLead
Innovate UK · Collaborative R&D · 2019-10-01 – 2020-12-31 · with 1 other participant
£22,402
awarded
Sixfold Bioscience Ltd.lead£22,402